Eliska Petrova

Ms. Eliska Petrova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
EPEliska Petrova
Eliska Petrova
SCStanislav Chvíla
Stanislav Chvíla
FŠFrantišek Štěpánek
František Štěpánek
Jarmila ZbytovskaJarmila Zbytovska
Jarmila Zbytovska
Dimitrios A. LamprouDimitrios A. Lamprou
Dimitrios A. Lamprou
The utilization of 3D printing– digital light processing (DLP) technique, for the direct fabrication of microneedles encounters the problem of drug solubility in printing resin, especially if it is predominantly composed of water. The possible solution how to ensure ideal belonging of drug and water-based printing resin is its pre-formulation in nanosuspension such as nanocrystals. This study investigates the feasibility of this approach on a resin containing nanocrystals of imiquimod (IMQ), an active used in (pre)cancerous skin conditions, well known for its problematic solubility and bioavailability. The resin blend of polyethylene glycol diacrylate and N-vinylpyrrolidone, and lithium phenyl-2,4,6-trimethylbenzoylphosphinate as a photoinitiator, was used, mixed with IMQ nanocrystals in water. The final microneedle-patches had 36 cylindrical microneedles arranged in a square grid, measuring approximately 600 μm in height and 500 μm in diameter. They contained 5wt% IMQ, which is equivalent to a commercially available cream. The homogeneity of IMQ distribution in the matrix was higher for nanocrystals compared to usual crystalline form. The release of IMQ from the patches was determined ex vivo in natural skin and revealed a 48% increase in efficacy for nanocrystal formulations compared to the crystalline form of IMQ. Graphical Abstract

4 November 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
EPEliska Petrova
Eliska Petrova
SCStanislav Chvíla
Stanislav Chvíla
MBMartin Balouch
Martin Balouch
FŠFrantišek Štěpánek
František Štěpánek
Jarmila ZbytovskaJarmila Zbytovska
Jarmila Zbytovska

3 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AKAneta Kalvodová
Aneta Kalvodová
KDKristyna Dvorakova
Kristyna Dvorakova
EPEliska Petrova
Eliska Petrova
Bozena Michniak-KohnBozena Michniak-Kohn
Bozena Michniak-Kohn
Jarmila ZbytovskaJarmila Zbytovska
Jarmila Zbytovska
Owing to their complicated pathophysiology, the treatment of skin diseases necessitates a complex approach. Conventional treatment using topical corticosteroids often results in low effectiveness and the incidence of local or even systemic side effects. Nanoformulation of potent anti-inflammatory drugs has been selected as an optimal strategy for enhanced topical delivery of corticosteroids. In order to assess the efficiency of various nanoformulations, we formulated hydrocortisone (HC) and hydrocortisone-17-butyrate (HCB) into three different systems: lipid nanocapsules (LNC), polymeric nanoparticles (PNP), and ethosomes (ETZ). The systems were characterized using dynamic light scattering for their particle size and uniformity and the morphology of nanoparticles was observed by transmission electron microscopy. The nanosystems were tested using ex vivo full thickness porcine and human skin for the delivery of HC and HCB. The skin penetration was observed by confocal microscopy of fluorescently labelled nanosystems. ETZ were proposed as the most effective delivery system for both transdermal and dermal drug targeting but were also found to have a profound effect on the skin barrier with limited restoration. LNC and PNP were found to have significant effects in the dermal delivery of the actives with only minimal transdermal penetration, especially in case of HCB administration.